Child and Adolescent Psychiatry
Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy

210

211

Address: Osianderstraße 14-16
72076 Tübingen

Emergency

frontend.sr-only_#{element.icon}: 07071 29-62465

Project completed

PURPOSE

Placebo-controlled trial in subjects at Ultra-high Risk for Psychosis with Omega-3 fatty acidS in Europe

The main objective of this clinical trial is to assess whether treatment with omega-3 fatty acids can prevent or delay the development of psychosis. Psychosis is a chronic and severe mental disorder that is usually preceded by a period of attenuated psychotic symptoms and functional disorders. Patients can hear voices, see things that are not there or feel like they are being followed.

Contact

If you would like to participate, have questions or are interested in the project, please contact us at

E-mail address: Elena.Mueller@med.uni-tuebingen.de

frontend.sr-only_#{element.icon}: +49 7071 29-80712

Publications

Selected publications

Flyer for the project

Methodology

It is a multi-center study that is being conducted in several European countries and Israel. In Germany, the trial centers Jena and Tübingen are participating. The study is initiated, organized and financed by the University Medical Center Utrecht in the Netherlands. Patients between 13 and 20 years of age who have an ultra-high risk of developing psychosis are eligible to participate. The treatment with omega-3 fatty acids or placebo lasts six months. Healthy control participants aged between 13 and 20 years can also participate in the study at the trial center in Tübingen.

Project participants and funding

Project participants

Prof. Dr. Tobias Renner
Dr. Gottfried Maria Barth, M.A.
Prof. Dr. Annette Conzelmann
Hanna Brauner
Sebastian Sennock
Eva Sitz
Elena Müller
Lena Kunert

Funding

Sponsor: Prof. René S. Kahn, Brain Center Rudolf Magnus, Department of Psychiatry, A01.126, University Medical Center Utrecht, The Netherlands

Publications

Winter-van Rossum I, Slot MIE, van Hell HH, Bossong MG, Berger G, Aschauer H, Maat A, Walitza S, Lavan O, Baeza I, Dolz M, Monducci E, Fiori Nastro P, Kroken RA, Lawrie SM, Díaz-Caneja CM, Renner T, Schlögelhofer M, Scharinger C, Spalletta G, Banaj N, Otero S, Schipper M, Kwakkel DB; PURPOSE Study Group; Kahn RS. Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial. Schizophr Bull. 2024 Oct 25:sbae186. doi: 10.1093/schbul/sbae186. Epub ahead of print. PMID: 39450759.
Find out more